Literature DB >> 2583156

Lipid profile of body builders with and without self-administration of anabolic steroids.

J Fröhlich1, T Kullmer, A Urhausen, R Bergmann, W Kindermann.   

Abstract

Twenty-four top-level body builders [13 anabolic steroid users (A); 11 non-users (N)] and 11 performance-matched controls (C) were examined to determine the effect on lipids, lipoproteins and apolipoproteins of many years of body building with and without simultaneous intake of anabolic steroids and testosterone. After an overnight fast, triglycerides (TG), total cholesterol (TOTC), high density lipoprotein cholesterol (HDLC), low density lipoprotein cholesterol (LDLC), the HDLC subfractions HDL2C and HDL3C, as well as apolipoprotein A-I (Apo A-I), apolipoprotein A-II (Apo A-II) and apolipoprotein B (Apo B) were determined. Both A and N, compared to C, showed significantly lower HDLC and higher LDLC concentrations, with the differences between A and C clearly pronounced. In a subgroup of 6 body builders taking anabolic steroids at the time of the study, HDLC, HDL2C, HDL3C, Apo A-I and Apo A-II were all significantly lower and LDLC was significantly higher than in a second subgroup of 7 body builders who had discontinued their intake of anabolic steroids at least 4 weeks prior to the study. In some single cases HDLC was barely detectable (2-7 mg.dl-1). The TG and TOTC remained unchanged. The present findings suggest that many years of body building among top-level athletes have no beneficial effect on lipoproteins and apolipoproteins. Simultaneous use of anabolic steroids results in part in extreme alterations in lipoproteins and apolipoproteins, representing an atherogenic profile. After discontinuing the use of anabolic steroids, the changes in lipid metabolism appear to be reversible.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2583156     DOI: 10.1007/bf02396586

Source DB:  PubMed          Journal:  Eur J Appl Physiol Occup Physiol        ISSN: 0301-5548


  27 in total

1.  Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders.

Authors:  J W Lenders; P N Demacker; J A Vos; P L Jansen; A J Hoitsma; A van 't Laar; T Thien
Journal:  Int J Sports Med       Date:  1988-02       Impact factor: 3.118

Review 2.  Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study.

Authors:  W B Kannel; W P Castelli; T Gordon
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

Review 3.  Plasma lipoproteins and physical activity: a review.

Authors:  B Dufaux; G Assmann; W Hollmann
Journal:  Int J Sports Med       Date:  1982-08       Impact factor: 3.118

4.  Androgens reduce HDL2-cholesterol and increase hepatic triglyceride lipase activity.

Authors:  M A Kantor; A Bianchini; D Bernier; S P Sady; P D Thompson
Journal:  Med Sci Sports Exerc       Date:  1985-08       Impact factor: 5.411

5.  High density lipoprotein cholesterol in young adult weight lifters, runners and untrained subjects.

Authors:  P M Clarkson; R Hintermister; M Fillyaw; L Stylos
Journal:  Hum Biol       Date:  1981-05       Impact factor: 0.553

6.  The assessment of the amount of fat in the human body from measurements of skinfold thickness.

Authors:  J V Durnin; M M Rahaman
Journal:  Br J Nutr       Date:  1967-08       Impact factor: 3.718

7.  Preliminary report: kinetic studies on the modulation of high-density lipoprotein, apolipoprotein, and subfraction metabolism by sex steroids in a postmenopausal woman.

Authors:  W R Hazzard; S M Haffner; R S Kushwaha; D Applebaum-Bowden; D M Foster
Journal:  Metabolism       Date:  1984-09       Impact factor: 8.694

8.  Changes in lipid and lipoprotein levels after weight training.

Authors:  L Goldberg; D L Elliot; R W Schutz; F E Kloster
Journal:  JAMA       Date:  1984-07-27       Impact factor: 56.272

9.  High-density-lipoprotein cholesterol in bodybuilders v powerlifters. Negative effects of androgen use.

Authors:  B F Hurley; D R Seals; J M Hagberg; A C Goldberg; S M Ostrove; J O Holloszy; W G Wiest; A P Goldberg
Journal:  JAMA       Date:  1984-07-27       Impact factor: 56.272

10.  Reduced high-density lipoprotein-cholesterol in power athletes: use of male sex hormone derivates, an atherogenic factor.

Authors:  M Alén; P Rahkila
Journal:  Int J Sports Med       Date:  1984-12       Impact factor: 3.118

View more
  9 in total

Review 1.  Drugs and sport. Research findings and limitations.

Authors:  P M Clarkson; H S Thompson
Journal:  Sports Med       Date:  1997-12       Impact factor: 11.136

2.  [Cardiovascular alterations associated with doping].

Authors:  D Thieme; A Büttner
Journal:  Herz       Date:  2015-05       Impact factor: 1.443

3.  Validity of self-report in identifying anabolic steroid use among weightlifters.

Authors:  G S Ferenchick
Journal:  J Gen Intern Med       Date:  1996-09       Impact factor: 5.128

Review 4.  Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm.

Authors:  Suraj Achar; Armand Rostamian; Sanjiv M Narayan
Journal:  Am J Cardiol       Date:  2010-09-15       Impact factor: 2.778

Review 5.  Health- and performance-related potential of resistance training.

Authors:  M H Stone; S J Fleck; N T Triplett; W J Kraemer
Journal:  Sports Med       Date:  1991-04       Impact factor: 11.136

6.  Resistance trained athletes using or not using anabolic steroids compared to runners: effects on cardiorespiratory variables, body composition, and plasma lipids.

Authors:  R Yeater; C Reed; I Ullrich; A Morise; M Borsch
Journal:  Br J Sports Med       Date:  1996-03       Impact factor: 13.800

Review 7.  Recent developments in the toxicology of anabolic steroids.

Authors:  S Graham; M Kennedy
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

8.  Plasma lipid concentrations in professional cyclists after competitive cycle races.

Authors:  P Mena; M Maynar; J E Campillo
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1991

9.  Global gene expression of fission yeast in response to cisplatin.

Authors:  L Gatti; D Chen; G L Beretta; G Rustici; N Carenini; E Corna; D Colangelo; F Zunino; J Bähler; P Perego
Journal:  Cell Mol Life Sci       Date:  2004-09       Impact factor: 9.261

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.